Tyrosine News and Research

RSS

New test for targeted therapy in acute myeloid leukemia

Oregon Health & Science University Cancer Institute researcher Jeff Tyner, Ph.D., has created a way to identify proteins that are candidates for targeted therapy in acute myeloid leukemia using an assay that yields results in just four days.

10 Dec 2007

Pathogens use previously undescribed mechanism to sabotage host immune system

New research identifies a previously unknown enzymatic mechanism that subverts the early host immune response and promotes pathogenicity by manipulating a common signaling pathway in host cells.

10 Dec 2007

Re-engineered Gleevec reduces heart risks

Using a new bottom-up approach for rational drug design, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have reengineered the powerful anticancer drug imatinib - best known by its brand name Gleevec - to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect.

4 Dec 2007

Modified form of imatinib becomes more specific

Imatinib (marketed as Gleevec in the US and Glivec in Europe and Australia) is used to treat various cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).

4 Dec 2007

Chemical peroxynitrite tolerates pain

The repeated use of opiate drugs such as morphine to relieve chronic pain results in individuals having to take higher and higher doses of the drug to achieve equivalent pain relief (they are said to exhibit antinociceptive tolerance).

2 Nov 2007

Blood markers can help choose best dose for antiangiogenic drugs

Scientists at Sunnybrook have new information that may help to improve the use of anti-cancer drugs designed to block the growth of new blood vessels in tumors, a process called angiogenesis that is critical to tumor growth.

25 Oct 2007

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007

New molecular evidence of the role of the hormone prolactin in breast cancer

They have found that prolactin, a pituitary hormone that normally stimulates breast development and milk production, initiates a new “signaling pathway” that may regulate the growth and survival of breast cancer cells.

29 Sep 2007

New molecular target in blood clot formation

Researchers at the University of Illinois at Chicago College of Medicine have identified a new molecular target in blood clot formation, which seems to reduce clotting without excessive bleeding, the common side-effect of anti-clotting agents.

27 Sep 2007

Study suggests brain tumors need treatment with multiple 'targeted' drugs

Researchers at Dana-Farber Cancer Institute have shown that several, rather than just one, cell-growth switches are simultaneously overactive in many brain tumors and other solid tumors, explaining why treatment with just a single "targeted" switch-blocking drug often yields disappointing results.

13 Sep 2007

Mechanism identified that plays a critical role in multiple myeloma cell cycle and survival

Researchers at Emory University's Winship Cancer Institute are the first to discover a mechanism that plays a critical role in the multiple myeloma cell cycle and survival.

11 Sep 2007

Congestive heart failure is rare among leukemia patients who take imatinib

Congestive heart failure rarely occurs among leukemia patients who take imatinib, researchers at The University of Texas M. D. Anderson Cancer Center found after an exhaustive review of the detailed medical histories of 1,276 patients who enrolled in clinical trials for the drug.

10 Sep 2007

Genetics of imatinib resistance in acute lymphoblastic leukemia

In the September 15th issue of Genes & Development, Drs. Richard T. Williams, Willem den Besten, and Charles J. Sherr at Howard Hughes Medical Institute, St. Jude Children's Research Hospital in Memphis TN, lend new insights into how an aggressive form of acute lymphoblastic leukemia (ALL) develops, and how sensitivity to the targeted chemotherapeutic drug, imatinib, can be diminished through interactions between tumor cells and the host microenvironment.

30 Aug 2007

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007

New advance in search for effective treatment for human liver cancer

Researchers from the University of Pittsburgh School of Medicine report a significant new advance in the search for an effective treatment for human liver cancer in the July issue of Molecular Cancer Therapeutics.

12 Jul 2007

Trastuzumab and chemo improves survival in women with operable HER-2 positive breast cancer

A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.

9 Jul 2007

Current status of neuroblastoma treatment and trends for the near future

Childhood cancers are fortunately rare, but among them, neuroblastoma is a special case, accounting for 7 percent of all childhood cancers, but 15 percent of childhood cancer deaths.

23 Jun 2007

Injected neural stem cells reduce Parkinson's symptoms in primates

Primates with severe Parkinson's disease were able to walk, move, and eat better, and had diminished tremors after being injected with human neural stem cells, a research team from Yale, Harvard, the University of Colorado, and the Burnham Institute report in Proceedings of the National Academy of Sciences.

14 Jun 2007